Mauro Bafutto

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease

Satish Keshav, Tomáš Vaňásek, Yaron Niv et al. · PLoS ONE · 2013 · 134 citations · Full text

Medicine, Immunology, Pharmacology +17

Laparoscopic management of choledocholithiasis

Aureo L. DePaula, Kiyoshi Hashiba, Mauro Bafutto · Surgical Endoscopy · 1994 · 95 citations

Medicine, Surgery, General Surgery +11

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Heda M B S Amarante et al. · World Journal of Gastroenterology · 2019 · 87 citations · Full text

Medicine, Health Sciences, Gastroenterology +13